Related Content
![Three doctors in white lab coats against a pink background Three doctors in white lab coats against a pink background](/sites/default/files/us/2023-05/Article%20-%20Press%20Release%20teaser%20cards.jpeg)
Pulmonary Fibrosis
FIBRONEER™ trials for IPF, other progressive fibrosing ILDs
Donald Zoz, M.D., Director and Senior Clinical Program Leader for Pulmonary Fibrosis at Boehringer Ingelheim, discusses the unmet needs of patients with IPF and other forms of progressive fibrosing ILDs and the FIBRONEER™ global clinical program
Read more
Related Press Release
![animation of child sitting on couch and smiling with caregiver](/sites/default/files/us/2023-07/snda.jpg)
July 25, 2023
FDA accepts OFEV sNDA for 6–17-year-olds with fibrosing ILD
![First patient enrolled in FIBRONEER™-IPF Phase III trial First patient enrolled in FIBRONEER™-IPF Phase III trial](/sites/default/files/us/2023-01/FIBRONEER.png)
October 26, 2022